Trial Profile
An Open-Label, Long-Term, Multiple-Dose, Safety and Tolerability, Pharmacokinetic Study of 150 mg eq. Paliperidone Palmitate in the Treatment of Subjects With Schizophrenia.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 17 Oct 2015
Price :
$35
*
At a glance
- Drugs Paliperidone (Primary)
- Indications Schizophrenia
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Janssen Research & Development
- 29 Jun 2010 New trial record